Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model

Thorax. 2007 Jun;62(6):527-35. doi: 10.1136/thx.2006.061945. Epub 2007 Jan 18.

Abstract

Background: Injurious mechanical ventilation can cause a pro-inflammatory reaction in the lungs. Recent evidence suggests an association of the renin-angiotensin system (RAS) with lung inflammation. A study was undertaken to investigate the pathogenic role of the RAS in ventilator-induced lung injury (VILI) and to determine whether VILI can be attenuated by angiotensin converting enzyme (ACE) inhibition.

Methods: Male Sprague-Dawley rats were mechanically ventilated for 4 h with low (7 ml/kg) or high (40 ml/kg) tidal volumes; non-ventilated rats were used as controls. Lung injury and inflammation were measured by the lung injury score, protein leakage, myeloperoxidase activity, pro-inflammatory cytokine levels and nuclear factor (NF)-kappaB activity. Expression of the RAS components was also assessed. Some rats were pretreated with the ACE inhibitor captopril (10 mg/kg) for 3 days or received a concomitant infusion with losartan or PD123319 (type 1 or type 2 angiotensin II receptor antagonist) during mechanical ventilation to assess possible protective effects on VILI.

Results: In the high-volume group (n=6) the lung injury score, bronchoalveolar lavage fluid protein concentration, pro-inflammatory cytokines and NF-kappaB activities were significantly increased compared with controls (n=6). Lung tissue angiotensin II levels and mRNA levels of angiotensinogen and type 1 and type 2 angiotensin II receptors were also significantly increased in the high-volume group. Pretreatment with captopril or concomitant infusion with losartan or PD123319 in the high-volume group attenuated the lung injury and inflammation (n=6 for each group).

Conclusions: The RAS is involved in the pathogenesis of ventilator-induced lung injury. ACE inhibitor or angiotensin receptor antagonists can attenuate VILI in this rat model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Blotting, Western
  • Bronchoalveolar Lavage Fluid / chemistry
  • Captopril / therapeutic use
  • Cytokines / metabolism
  • Lung Diseases / etiology*
  • Lung Diseases / prevention & control
  • Male
  • NF-kappa B / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Renin-Angiotensin System / physiology*
  • Respiration, Artificial / adverse effects*
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Ventilators, Mechanical

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Cytokines
  • NF-kappa B
  • RNA, Messenger
  • Captopril